TABLE III.

Effect of omalizumab on rhinovirus-induced PBMC expression of IFN-α signaling and responsiveness genes^*

	Omalizumab					Placebo
mRNA expression†	No.	Prerandomization, mean (SD)	Postrandomization, mean (SD)	Ratio of geometric means (95% CI)	P value	No.	Prerandomization, mean (SD)	Postrandomization, mean (SD)	Ratio of geometric means (95% CI)	P value
TLR7	56	2.5 (2.2)	3.0 (2.3)	1.21 (0.94–1.55)	.13	22	2.6 (2.1)	2.4 (2.0)	0.94 (0.66–1.34)	.73
IRF7	56	7.1 (3.4)	7.6 (2.7)	1.07 (0.75–1.54)	.70	22	8.0 (2.8)	5.9 (2.8)	0.74 (0.45–1.21)	.21
IFNB1	55	23.8 (11.6)	46.4 (8.8)	1.95 (1.04–3.66)	.04	20	27.2 (7.2)	20.7 (8.2)	0.76 (0.28–2.05)	.57
IFNA1‡	32	17.9 (11.5)	32.0 (12.5)	1.79 (0.65–4.94)	.25	13	65.4 (6.5)	24.2 (5.6)	0.37 (0.12–1.15)	.08
DDX58 (RIG-I)	56	6.2 (3.6)	8.9 (2.8)	1.43 (1.03–1.99)	.04	22	9.1 (2.7)	6.4 (3.3)	0.7 (0.41–1.22)	.20
IFIT1	56	44.8 (13.2)	75.5 (8.5)	1.69 (0.85–3.34)	.13	22	65.9 (8.0)	24.5 (10.9)	0.37 (0.14–1.01)	.05

Boldface indicates P < .05.

^*Means are geometric means, and SDs are geometric SDs.

^†Cells were stimulated ex vivo with anti-IgE plus rhinovirus and mRNA expression of demonstrated genes normalized to HPRT expression (2^−Δct).

^‡Measuring transcriptional levels of total IFN-α was not feasible given the existence of at least 12 distinct IFN-α subtypes.